Salix Pharmaceuticals is seeking Food and Drug Administration approval for a new dosage of its ulcerative colitis drug Colazal.

Salix said Tuesday it had filed a new drug application with the FDA seeking a 1100 milligram tablet in addition to the currently available 750 mg. The larger dosage would permit twice-a-day dosage, the company said.

The FDA could review the application in 10 months, Salix said.